DEVOTISSE
DEAD

Serial Number

87335704

Owner

ALLERGAN SALES, LLC

Filing Date

Feb 14, 2017

Add to watchlist:

No watchlists yet
View on USPTO

DEVOTISSE Trademark

Serial Number: 87335704

DEVOTISSE is a trademark filed by ALLERGAN SALES, LLC on February 14, 2017. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

ALLERGAN SALES, LLC (490 trademarks)

5 GIRALDA FARMS
MADISON, NJ 07940

Entity Type: 16

Trademark Details

Filing Date

February 14, 2017

Registration Date

Not Registered

Goods & Services

Pharmaceutical preparations used in connection with anti-aging, namely, for use in the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin; Pharmaceutical preparations used in connection with and for facial aesthetic surgery, facial aesthetic reconstruction, and breast aesthetic treatment procedures; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma agents and decongestant formulations; sterile antibiotic ointments; ocular contact lens wetting solutions, artificial tears and pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lightener lotions and creams; Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing pharmaceutical preparations; Pharmaceutical preparations and medicines for the treatment and prevention of sexual dysfunction; Pharmaceutical preparations and medicines for the treatment of sensory organ disorders; Pharmaceutical preparations and medicines for the treatment of urogenital organ disorders; Pharmaceutical preparations and medicines for the treatment of circulatory system disorders; Pharmaceutical preparations and medicines for the treatment of cardiovascular and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceutical and cosmeceutical preparations for skin care, namely, medicated skin cleansers, toners, moisturizers, rejuvenators, rehydrating creams, and lotions for the face and body

Filing History

ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Jan 17, 2019 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Jan 17, 2019 ABN2
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jun 21, 2018 GNRN
NON-FINAL ACTION E-MAILED
Jun 21, 2018 GNRT
NON-FINAL ACTION WRITTEN
Jun 21, 2018 CNRT
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
May 31, 2018 RCCK
ASSIGNED TO LIE
May 31, 2018 ALIE
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Nov 13, 2017 RCSC
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
May 12, 2017 GNS3
LETTER OF SUSPENSION E-MAILED
May 12, 2017 GNSL
SUSPENSION LETTER WRITTEN
May 12, 2017 CNSL
EXAMINER'S AMENDMENT ENTERED
May 12, 2017 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
May 12, 2017 GNEN
EXAMINERS AMENDMENT E-MAILED
May 12, 2017 GNEA
EXAMINERS AMENDMENT -WRITTEN
May 12, 2017 CNEA
ASSIGNED TO EXAMINER
May 9, 2017 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 21, 2017 NWOS
NEW APPLICATION ENTERED
Feb 17, 2017 NWAP